Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vera Therapeutics Inc | VERA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 41.39 | 07:09:48 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 41.39 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 7.10 - 50.78 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 41.39 | USD |
Vera Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.84B | 44.43M | - | 0 | -95.99M | -2.16 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Vera Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VERA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 41.63 | 43.81 | 39.67 | 41.48 | 475,148 | -0.24 | -0.58% |
| 1 Month | 38.00 | 48.51 | 37.80 | 41.66 | 798,369 | 3.39 | 8.92% |
| 3 Months | 47.40 | 50.78 | 35.855 | 43.26 | 974,097 | -6.01 | -12.68% |
| 6 Months | 13.63 | 50.78 | 12.28 | 35.07 | 1,021,720 | 27.76 | 203.67% |
| 1 Year | 7.86 | 50.78 | 7.10 | 26.82 | 839,130 | 33.53 | 426.59% |
| 3 Years | 15.33 | 50.78 | 5.20 | 21.88 | 411,584 | 26.06 | 169.99% |
| 5 Years | 11.41 | 50.78 | 5.20 | 21.86 | 410,258 | 29.98 | 262.75% |
Vera Therapeutics Description
| Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
